Eurazeo finalizes the sale of Dutch Ophthalmic Research Center (DORC) to Carl Zeiss Meditec, one of the world's leading medical technology companies.

DORC is a leading and fast-growing ophthalmic surgery platform in the vitreoretina (' VR ') and cataract markets.

Eurazeo has supported DORC's growth, consolidating its sector expertise and accelerating its international expansion, particularly in the United States and Asia.
.
The transaction materializes a gross return of 2.6 x cash-on-cash and a gross internal rate of return (IRR) of 24% on the initial investment, with approximately 386 ME of gross proceeds from the sale returning to Eurazeo's balance sheet.

Copyright (c) 2024 CercleFinance.com. All rights reserved.